Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide (AM833) Long acting amylin analog. Beta cells make TWO hormones: insulin and amylin. Amylin slows stomach emptying and reduces appetite. Cagrilintide is a long acting synthetic amylin designed for once weekly dosing Weight Loss of 10% Within 2 Weeks? Evaluating Amylin Analogs in Diet Induced Obese (DIO) Rat Model_GemPharmatech